The 15 most recent market catalysts affecting $XENE, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Sep 18, 2026
Market Technicals
Bearish
Impact 65
Dow Falls Over 200 Points; Xenon Pharmaceuticals Shares Plunge
The filing details a broad market decline on Friday, with the Dow, NASDAQ, and S&P 500 all trading lower. This general market weakness is attributed to disappointing U.S. industria…
Sep 18, 2026
Corporate Catalyst
Bearish
Impact 65
RBC Capital Maintains Outperform on Xenon Pharmaceuticals, Lowers Price Target to $70
RBC Capital analyst Brian Abrahams maintained an 'Outperform' rating on Xenon Pharmaceuticals (XENE) but lowered the price target from $81 to $70. This action signals that while th…
Sep 18, 2026
Corporate Catalyst
Bearish
Impact 55
Wedbush Maintains Outperform on Xenon Pharmaceuticals, Lowers Price Target to $55
Wedbush analyst Laura Chico has maintained an 'Outperform' rating on Xenon Pharmaceuticals (XENE) but significantly lowered the price target from $71 to $55. This action suggests t…
Sep 18, 2026
Corporate Catalyst
Bearish
Impact 55
Wells Fargo Maintains Overweight on Xenon Pharmaceuticals, Lowers Price Target to $64
Wells Fargo analyst Benjamin Burnett maintained an 'Overweight' rating on Xenon Pharmaceuticals (XENE), signaling a continued belief in the company's long-term potential. However, …
Sep 18, 2026
Corporate Catalyst
Bearish
Impact 75
Xenon Pharmaceuticals, Steel Dynamics, Nucor And Other Big Stocks Moving Lower In Friday’s Pre-Market Session
Xenon Pharmaceuticals is experiencing a significant negative catalyst as it voluntarily pauses new patient enrollment in its major depressive disorder and bipolar depression studie…
Sep 18, 2026
Corporate Catalyst
Bearish
Impact 85
Xenon Pharmaceuticals shares are trading lower after the company announced it voluntarily initiated a temporary pause of enrollment of new patients in ongoing psychiatry studies. Multiple firms lowered their respective price targets on the stock.
The voluntary pause in new patient enrollment for Xenon Pharmaceuticals' psychiatry studies is a major negative corporate catalyst. This action signals potential issues or re-evalu…
Sep 18, 2026
Market Technicals
Bearish
Impact 75
Deutsche Bank Downgrades Xenon Pharmaceuticals to Hold, Lowers Price Target to $46
Deutsche Bank analyst David Hoang downgraded Xenon Pharmaceuticals (XENE) from a 'Buy' to a 'Hold' rating and slashed the price target by nearly 50%, from $90 to $46. This signific…
Sep 18, 2026
Corporate Catalyst
Bearish
Impact 55
Baird Maintains Outperform on Xenon Pharmaceuticals, Lowers Price Target to $90
Baird analyst Brian Skorney maintained an 'Outperform' rating for Xenon Pharmaceuticals (XENE), indicating a continued positive long-term outlook for the company. However, the pric…
Sep 17, 2026
Corporate Catalyst
Bearish
Impact 85
Xenon Pharmaceuticals shares are trading lower after the company announced it voluntarily initiated a temporary pause of enrollment of new patients in ongoing psychiatry studies.
The voluntary pause in new patient enrollment for Xenon Pharmaceuticals' psychiatry studies is a significant negative catalyst. This action often indicates an unexpected issue, suc…
Sep 17, 2026
Corporate Catalyst
Bearish
Impact 75
Xenon Pharmaceuticals Announces Voluntarily Initiated A Temporary Pause Of Enrollment Of New Patients In Ongoing Psychiatry Studies Following Neuropsychiatric Adverse Events; Patients Currently Enrolled In The Ongoing Studies Remain Active
Xenon Pharmaceuticals announced a voluntary pause on new patient enrollment in its ongoing clinical studies for major depressive disorder (MDD) and bipolar depression (BPD). This d…
Sep 17, 2026
Corporate Catalyst
Bullish
Impact 75
Xenon Pharmaceuticals Says X-NOVA2 Enrollment Reaches ~80% Of Its Initial Target Of 450 Patients; Topline Data Readout Expected Q1 2027
Xenon Pharmaceuticals has updated the market on the progress of its X-NOVA2 trial, indicating that enrollment is nearing completion at 80% of its initial target. This is a signific…
Aug 26, 2026
Corporate Catalyst
Neutral
Impact 65
Xenon Pharmaceuticals To Present 6 Azetukalner Data Sets, Including Encore Oral Presentation Of Topline Phase 3 X-TOLE2 Results At European Epilepsy Congress, Taking Place September 5-9, 2026
Xenon Pharmaceuticals (XENE) announced it will present six data sets for its lead drug candidate, azetukalner, at the European Epilepsy Congress in September 2026. This includes an…
Aug 7, 2026
Corporate Catalyst
Bearish
Impact 55
RBC Capital Maintains Outperform on Xenon Pharmaceuticals, Lowers Price Target to $81
RBC Capital's analyst Brian Abrahams has maintained an 'Outperform' rating on Xenon Pharmaceuticals (XENE), indicating a continued positive long-term view on the company's prospect…
Aug 6, 2026
Corporate Catalyst
Bearish
Impact 92
Xenon Pharmaceuticals Q2 EPS $(1.11) Beats $(1.15) Estimate
Xenon Pharmaceuticals announced its Q2 earnings, reporting a loss of $(1.11) per share. While this figure surpassed the analyst consensus estimate of $(1.15), it's crucial to note …
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.